For AD, 76% of agents in phase III trials in 2016 were disease-modifying therapies, including amyloid- and tau-targeted agents, whereas by 2022, only 29% of the agents in phase III trials were disease-modifying therapies62,63. Here, MAPT is linked to Alzheimer disease.